{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(11)"],"submitter":["Hayashi H"],"pubmed_abstract":["<h4>Purpose</h4>Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on the occurrence and grade of irAEs.<h4>Patients and methods</h4>We used data from Japanese patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who received atezolizumab and were enrolled in J-TAIL, a multicenter, prospective, single-arm observational study.<h4>Results</h4>Among the 1,002 patients, 190 (19.0%) developed irAEs. The most common irAEs were skin disorders (3.8%) of any grade and interstitial lung disease (1.5%) of grade ≥3. Patients who developed irAEs within 4 or 6 weeks of treatment initiation had"],"journal":["Cancer research communications"],"pagination":["2858-2867"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528261"],"repository":["biostudies-literature"],"pubmed_title":["Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer."],"pmcid":["PMC11528261"],"pubmed_authors":["Takase N","Tasaka S","Gemma A","Fujita M","Takamura K","Yoshino I","Mouri A","Goto Y","Misumi T","Kijima T","Miura S","Imaizumi K","Iwasawa S","Mitsudomi T","Akamatsu H","Nishio M","Kondo T","Kawashima Y","Hayashi H","Nakagawa S"],"additional_accession":[]},"is_claimable":false,"name":"Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.","description":"<h4>Purpose</h4>Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on the occurrence and grade of irAEs.<h4>Patients and methods</h4>We used data from Japanese patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who received atezolizumab and were enrolled in J-TAIL, a multicenter, prospective, single-arm observational study.<h4>Results</h4>Among the 1,002 patients, 190 (19.0%) developed irAEs. The most common irAEs were skin disorders (3.8%) of any grade and interstitial lung disease (1.5%) of grade ≥3. Patients who developed irAEs within 4 or 6 weeks of treatment initiation had","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-02T23:01:01.856Z","creation":"2025-04-04T22:47:21.081Z"},"accession":"S-EPMC11528261","cross_references":{"pubmed":["39392339"],"doi":["10.1158/2767-9764.CRC-24-0212"]}}